Dell Powering the Possible

Since the 1980s, the FDA has approved one new treatment for any type of childhood cancer, compared with 50 approved treatments for adult cancers during the same time period. Dell believes in the power of technology to unlock new possibilities and advanced treatment options for pediatric cancer beyond today's "trial and error" methods. Dell is committed to providing the IT infrastructure, corporate funding and employee volunteers to support this cause.

NMTRC 2012 Symposium
Dell is hosting the annual symposium of the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), May 16–17 at Dell Children’s Medical Center in Austin. NMTRC’s extended team of biomedical researchers, pediatric oncologists, parents and advocates will be providing an update on the groundbreaking personalized medicine clinical trial that Dell is proudly supporting.



Join us to watch the Dell LiveStram Broadcast from the Dell Children's Hospital of Central Texas.
Courtesy of www.fittotweet.com

Fight Pediatric Cancer Day
In recognition of this important research endeavor and its ties to Central Texas, the cities of Austin and Round Rock have proclaimed May 16, 2012, as Fight Pediatric Cancer Day.

View PDF	Fight Pediatric Cancer Day — City of Austin Proclamation In conjunction with the NMTRC 2012 Symposium held at the Dell Children's Hospital of Central Texas and in recognition of Dell's ongoing efforts, Lee Leffingwell, Mayor of the City of Austin, Texas, has declared May, 16, 2012, as Fight Pediatric Cancer Day in Austin.
View PDF	Fight Pediatric Cancer Day — City of Round Rock Proclamation In conjunction with the NMTRC 2012 Symposium held at the Dell Children's Hospital of Central Texas and in recognition of Dell's ongoing efforts, Alan McGraw, Mayor of the City of Round Rock, Texas, has declared May, 16, 2012, as Fight Pediatric Cancer Day in Round Rock.

Learn more about the disease, the medical science and the technology enabling its research.

	Neuroblastoma — View the fact sheet Personalized medicine is offering new hope to neuroblastoma patients. The Neuroblastoma and Medulloblastoma Translational Research Consortium is conducting a first-of-its-kind genomic-based clinical trial to treat and study pediatric cancer — specifically relapsed and refractory neuroblastoma.
	Genomics and molecular medicine — View the fact sheet The increased understanding of molecular medicine is shifting clinical practice from treatment based on symptoms to treatment based on the underlying causes of disease. This will enable physicians to prescribe treatment plans that are designed more intelligently, work more effectively and have fewer toxic side effects.
	Cloud computing — View the fact sheet The cloud is the embodiment of a future-ready infrastructure that makes it possible to create a true healthcare "system." This ideal system — in which information is secure but accessible to those who need it — streamlines administration, enhances care quality and supports personalized medicine.
For additional information visit these sites on Dell.com: Helping accelerate treatment for pediatric cancer with Dell cloud technology Dell healthcare and life sciences

See how the Cloud is working to power advancement in fighting pediatric cancer.

Dell to host NMTRC Symposium 2012, annual meeting of biomedical researchers, pediatric oncologists, parents and advocates, where innovators in pediatric cancer will share progress on a ground-breaking personalized medicine clinical trial.

What?

The team of parents, genetic and translational medicine scientists and pediatric oncologists trailblazing personalized medicine in the treatment of deadly pediatric cancers is convening in Austin to discuss the status of the world’s first personalized medicine clinical trial for pediatric cancer and plan next steps at the NMTRC Symposium 2012. Neuroblastoma affects 1 in 100,000 children and is responsible for 1 in 7 pediatric cancer deaths.

Who?

Parents, advocates, oncologists from the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) and biomedical researchers from the Translational Genomics Research Institute (TGen), who are using high performance computing and cloud technology from Dell to identify targeted treatments based on the specific genetic vulnerabilities of each child’s tumor — an approach that could be used to treat all pediatric and adult cancers in the future.

Why?

Personalized medicine — treatment based on the specific vulnerabilities of each tumor — is overcoming longstanding barriers to treatment of pediatric cancer. There has been only one new treatment for pediatric cancer approved by the FDA since the 1980s, compared to 50 treatments approved for adult cancer in this same timeframe. As a result, pediatric oncologists use treatments designed for adults to treat children, with toxic side effects that are frequently as physically detrimental to the child as the cancer itself.

When?

May 16, 1–2 pm CT
Keynote: "Molecular-Profiling for Optimized Precision Therapy"

Dr. Timothy Triche University of Southern California/ Children’s Hospital Los Angeles

May 16, 2–4 pm CT
Panel Discussion: "Kids Cloud: Access to Data Boundaries"

Dr. Melinda Merchant National Cancer Institute	Dr. Gary Marchant Arizona State University
Nancy Goodman Kids V. Cancer Foundation	Patrick Lacey Friends of Will Foundation
Andy Mikulak Max’s Ring of Fire Foundation	Dr. Giselle Sholler Van Andel Institute
Dr. Spyro Mousses Translational Genomics Research Institute	Dr. James Coffin Dell

Where?

Join us to watch the Dell LiveStream Broadcast of the event from Dell Children's Hospital in Austin, Texas.
Courtesy of Fittotweet: http://www.fittotweet.com/live/nmtrc/

Participate and join the conversation via the #HealthCloud hashtag on Twitter

05/17/2012 from dell.com/newsroom	New Research Computing Cluster for Childhood Cancer Ready to Help Fast-Track Targeted Treatments The childhood cancer research computing cluster created and donated by Dell for the Translational Genomics Research Institute (TGen) is ready to support the world’s first precision medicine clinical trial for pediatric cancer.
05/16/2012 from rmhc-austin.org	Dell Awards $100,000 Grant to Ronald McDonald House Charities for Work in 14 U.S. Cities Ronald McDonald House Charities has received a $100,000 Powering the Possible grant from Dell to support programs for families with children undergoing pediatric cancer treatment.
05/08/2012 from businesswire.com	Innovators in Pediatric Cancer to Share Progress on Groundbreaking Personalized Medicine Clinical Trial Dell to host NMTRC Symposium 2012, annual meeting of biomedical researchers, pediatric oncologists, parents and advocates.
03/29/2012 from dell.com/newsroom	Computerworld Recognizes Dell for Support of Childhood Cancer Research  IDG’s Computerworld Honors Program has recognized Dell as a 2012 Laureate for its commitment in support of childhood cancer care research globally.
11/10/2011 from dell.com/newsroom	Dell Commits Funding, Cloud Technology and Employee Engagement to Fight Neuroblastoma and Other Pediatric Cancers Dell launches new multimillion dollar, multiyear commitment to pediatric cancer as expansion of company’s overall philanthropic program — Dell Powering the Possible.
11/10/2011 from Direct2Dell	Powering the Possible for Those Battling Pediatric Cancer Today we announced the expansion of our giving efforts, Powering the Possible, to help fight pediatric cancer. And I’m really proud of this new extension.

Karen Quintos	Dr. Jeff Trent	Dr. Jeff Trent
"Finding a treatment for this disease is so important to Dell's leadership team"	"Thank you to Dell"	"What you'll hear during the Symposium"

View Highlights on Flickr from the Keynote at the NMTRC 2012 Symposium from Dell
Children's Hospital of Central Texas on May 16, 2012.



View the video archive of Dell's November 10th press briefing by clicking on the
video image.